Clinical Trial

Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 26, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).
Trial Details
NCT Number NCT07303712
Lead Sponsor Palo Alto Veterans Institute for Research
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 12 participants
Start Date 2024-08-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-26